Prana Biotechnology Receives Key Patent Grant by European Patent Office (PBT.AX, 00974980, 20090805)

Make Y!7 My Home Page

Huntleys' Stock of the Week

FINANCE NEWS

Other Resources
- RSS Feeds
- Message Boards

Finance Videos

Marketplace

Prana Biotechnology Receives Key Patent Grant by European Patent Office
Wednesday August 5, 2009, 9:27 am

Original Announcement: Prana is Granted Key Patent by European Patent Office

Prana Biotechnology announced that it has secured a key patent protecting its clinical drug asset PBT2, with the European Patent Office issuing a notice of Decision to Grant in Europe. The patent entitled "8-Hydroxyquinoline derivatives" covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2 and the uses of such compounds for the treatment of neurological diseases, including Alzheimer's Disease and Huntington's Disease. The European patent has a twenty year term expiring on 16 July 2023, with a possible extension of term of up to 5 years under supplementary protection provisions. The Company's lead Alzheimer's Disease compound, PBT2, has already completed a Phase IIa study in early Alzheimer's Disease patients and has demonstrated safety and tolerability.

More information about PBT.AX